Optimal dosing of warfarin and other coumarin anticoagulants: The role of genetic polymorphisms

Archives of Toxicology

Volumn 87, Issue 3, 2013, Pages 407-420

  Daly, Ann K ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Coumarin anticoagulant; Cytochrome P450; Pharmacogenetics; Vitamin K epoxide reductase; Warfarin

Indexed keywords

ACENOCOUMAROL; APOLIPOPROTEIN E; COUMARIN ANTICOAGULANT; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; PHENPROCOUMON; WARFARIN;

APOLIPOPROTEIN E GENE; CALUMENIN GENE; CYTOCHROME P450 2C18 GENE; CYTOCHROME P450 2C19 GENE; CYTOCHROME P450 2C9 GENE; CYTOCHROME P450 4F2 GENE; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; ETHNICITY; GAMMA GLUTAMYL CARBOXYLASE GENE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MICROSOMAL EPOXIDE HYDROLASE GENE; NONHUMAN; OPTIMAL DRUG DOSE; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VITAMIN K EPOXIDE REDUCTASE GENE;

ALGORITHMS; ANIMALS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; BLOOD COAGULATION; CONTINENTAL POPULATION GROUPS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DOSAGE CALCULATIONS; DRUG MONITORING; GENOTYPE; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MIXED FUNCTION OXYGENASES; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS; WARFARIN;

EID: 84878836176     PISSN: 03405761     EISSN: 14320738     Source Type: Journal    
DOI: 10.1007/s00204-013-1013-9     Document Type: Review

References (123)

1. Aithal GP, Day CP, Kesteven PJL, Daly AK (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. Lancet 353:717-719
2. Aklillu E, Leong C, Loebstein R, Halkin H, Gak E (2008) VKORC1 Asp36Tyr warfarin resistance marker is common in Ethiopian individuals. Blood 111:3903-3904
3. Anderson JL, Horne BD, Stevens SM et al (2007) Randomized trial of genotype-guided versus standard warfarin dosing in patients initiating oral anticoagulation. Circulation 116:2563-2570
4. Anderson JL, Horne BD, Stevens SM et al (2012) A randomized and clinical effectiveness trial comparing two pharmacogenetic algorithms and standard care for individualizing warfarin dosing (CoumaGen-II). Circulation 125:1997-2005
5. Avery PJ, Jorgensen A, Hamberg AK, Wadelius M, Pirmohamed M, Kamali F (2011) A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy. Clin Pharmacol Ther 90:701-706
6. Bae JW, Kim HK, Kim JH et al (2005) Allele and genotype frequencies of CYP2C9 in a Korean population. Br J Clin Pharmacol 60:418-422
7. Biss TT, Avery PJ, Brandao LR et al (2012) VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. Blood 119:868-873
8. Blaisdell J, Jorge-Nebert LF, Coulter S et al (2004) Discovery of new potentially defective alleles of human CYP2C9. Pharmacogenetics 14:527-537
9. Borobia AM, Lubomirov R, Ramirez E et al (2012) An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in spanish patients with thromboembolic disease. PLoS ONE 7:e41360
10. Burmester JK, Berg RL, Yale SH et al (2011) A randomized controlled trial of genotype-based Coumadin initiation. Genet Med 13:509-518
11. Cain D, Hutson SM, Wallin R (1998) Warfarin resistance is associated with a protein component of the vitamin K 2,3-epoxide reductase enzyme complex in rat liver. Thromb Haemost 80:128-133
12. Caldwell MD, Berg RL, Zhang KQ et al (2007) Evaluation of genetic factors for warfarin dose prediction. Clin Med Res 5:8-16
13. Caldwell MD, Awad T, Johnson JA et al (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111:4106-4112
14. Caraco Y, Blotnick S, Muszkat M (2008) CYP2C9 genotype-guided warfarin prescribing enhances the efficacy and safety of anticoagulation: a prospective randomized controlled study. Clin Pharmacol Ther 83:460-470
15. Carrasco-Garrido P, de Andres LA, Barrera VH, de Miguel GA, Jimenez-Garcia R (2010) Trends of adverse drug reactions related- hospitalizations in Spain (2001-2006). BMC Health Serv Res 10:287
16. Cavallari LH, Butler C, Langaee TY et al (2011) Association of apolipoprotein E genotype with duration of time to achieve a stable warfarin dose in African-American patients. Pharmacotherapy 31:785-792
17. Cavallari LH, Perera M, Wadelius M et al (2012) Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in African Americans. Pharmacogenet Genomics 22:152-158
18. Cha PC, Mushiroda T, Takahashi A et al (2010) Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 19:4735-4744
19. Chan SL, Thalamuthu A, Goh BC et al (2011) Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population. Pharmacogenet Genomics 21:35-41
20. Chen LY, Eriksson N, Gwilliam R, Bentley D, Deloukas P, Wadelius M (2005) Gamma-glutamyl carboxylase (GGCX) microsatellite and warfarin dosing. Blood 106:3673-3674
21. Cho HJ, On YK, Bang OY et al (2011) Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation. Clin Ther 33:1371-1380
22. Ciccacci C, Paolillo N, Di Fusco D, Novelli G, Borgiani P (2011) EPHX1 polymorphisms are not associated with warfarin response in an Italian population. Clin Pharmacol Ther 89:791 author reply 792
23. Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139-1151
24. Cooper GM, Johnson JA, Langaee TY et al (2008) A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood 112:1022-1027
25. Crespi CL, Miller VP (1997) The R144C change in the CYP2C9*2 allele alters interaction of the cytochrome P450 with NADPH:cytochrome P450 oxidoreductase. Pharmacogenetics 7:203-210
26. D'Andrea G, D'Ambrosio RL, Di Perna P et al (2005) A polymorphism in VKORC1 gene is associated with an inter-individual variability in the dose-anticoagulant effect of warfarin. Blood 105:645-649
27. Daly AK (2010) Genome-wide association studies in pharmacogenomics. Nat Rev Genet 11:241-246
28. Dickmann LJ, Rettie AE, Kneller MB et al (2001) Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. Mol Pharmacol 60:382-387
29. Do EJ, Lenzini P, Eby CS et al. (2012) Genetics informatics trial (GIFT) of warfarin to prevent deep vein thrombosis (DVT): rationale and study design. Pharmacogenomics J 12:417-424
30. Epstein RS, Moyer TP, Aubert RE et al (2010) Warfarin genotyping reduces hospitalization rates results from the MM-WES (Medco-Mayo Warfarin Effectiveness study). J Am Coll Cardiol 55:2804-2812
31. French B, Joo J, Geller NL et al (2010) Statistical design of personalized medicine interventions: the Clarification of Optimal Anticoagulation through Genetics (COAG) trial. Trials 11:108
32. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL (2004a) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91:87-94
33. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, McLeod HL (2004b) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91:87-94
34. Gong IY, Tirona RG, Schwarz UI et al (2011) Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118:3163-3171
35. Guenthner TM, Cai D, Wallin R (1998) Co-purification of microsomal epoxide hydrolase with the warfarin-sensitive vitamin K1 oxide reductase of the vitamin K cycle. Biochem Pharmacol 55:169-175
36. Haining RL, Hunter AP, Veronese ME, Trager WF, Rettie AE (1996) Allelic variants of human cytochrome P450 2C9: Baculovirus- mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch Biochem Biophys 333:447-458
37. Harrington DJ, Gorska R, Wheeler R et al (2008) Pharmacodynamic resistance to warfarin is associated with nucleotide substitutions in VKORC1. J Thromb Haemost 6:1663-1670
38. Hassett C, Aicher L, Sidhu JS, Omiecinski CJ (1994) Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3:421-428
39. Herman D, Peternel P, Stegnar M, Breskvar K, Dolzan V (2006) The influence of sequence variations in factor VII, gamma-glutamyl carboxylase and vitamin K epoxide reductase complex genes on warfarin dose requirement. Thromb Haemost 95:782-787
40. Higashi MK, Veenstra DL, Kondo LML et al (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. J Am Med Assoc 287:1690-1698
41. Hillman MA, Wilke RA, Caldwell MD, Berg RL, Glurich I, Burmester JK (2004) Relative impact of covariates in prescribing warfarin according to CYP2C9 genotype. Pharmacogenetics 14:539-547
42. Howard R, Leathart JBS, French DJ et al (2011) Genotyping for CYP2C9 and VKORC1 alleles by a novel point of care assay with HyBeacon (R) probes. Clin Chim Acta 412:2063-2069
43. Jorgensen AL, Al-Zubiedi S, Zhang JE et al (2009) Genetic and environmental factors determining clinical outcomes and cost of warfarin therapy: a prospective study. Pharmacogenet Genomics 19:800-812
44. Kamali F, Khan TI, King BP et al (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75:204-212
45. Kidd RS, Curry TB, Gallagher S, Edeki T, Blaisdell J, Goldstein JA (2001) Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin. Pharmacogenetics 11:803-808
46. Kimmel SE, Christie J, Kealey C et al (2008) Apolipoprotein E genotype and warfarin dosing among Caucasians and African Americans. Pharmacogenomics J 8:53-60
47. King BP, Khan TI, Aithal GP, Kamali F, Daly AK (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism. Pharmacogenetics 14:813-822
48. King CR, Deych E, Milligan P et al (2010) Gamma-glutamyl carboxylase and its influence on warfarin dose. Thromb Haemost 104:750-754
49. Klein TE, Altman RB, Eriksson N et al (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360:753-764
50. Kohn MH, Pelz HJ (2000) A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans. Blood 96:1996-1998
51. Kohnke H, Sorlin K, Granath G, Wadelius M (2005) Warfarin dose related to apolipoprotein E (APOE) genotype. Eur J Clin Pharmacol 61:381-388
52. Kurnik D, Qasim H, Sominsky S et al (2012) Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. Thromb Haemost 108:781-788
53. Lacut K, Ayme-Dietrich E, Gourhant L et al (2012) Impact of genetic factors (VKORC1, CYP2C9, CYP4F2 and EPHX1) on the anticoagulation response to fluindione. Br J Clin Pharmacol 73:428-436
54. Lee MT, Chen CH, Chou CH et al (2009) Genetic determinants of warfarin dosing in the Han-Chinese population. Pharmacogenomics 10:1905-1913
55. Lenzini P, Wadelius M, Kimmel S et al (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87:572-578
56. Li T, Chang CY, Jin DY, Lin PJ, Khvorova A, Stafford DW (2004) Identification of the gene for vitamin K epoxide reductase. Nature 427:541-544
57. Limdi NA, Arnett DK, Goldstein JA et al (2008) Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans. Pharmacogenomics 9:511-526
58. Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM (2009) Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy. Blood Cells Mol Dis 43:119-128
59. Limdi NA, Wadelius M, Cavallari L et al (2010) Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood 115:3827-3834
60. Liu Y, Jeong H, Takahashi H et al (2012) Decreased warfarin clearance associated with the CYP2C9 R150H (*8) polymorphism. Clin Pharmacol Ther 91:660-665
61. Loebstein R, Vecsler M, Kurnik D, Austerweil N, Halkin H, Almog S (2005) Common genetic variants of microsomal epoxide hydrolase affect warfarin dose requirements beyond the effect of cytochrome P4502C9. Clin Pharmacol Ther 77:365-372
62. Loebstein R, Dvoskin I, Halkin H et al (2007) A coding VKORC1 Asp36Tyr polymorphism predisposes to warfarin resistance. Blood 109:2477-2480
63. Lund K, Gaffney D, Spooner R, Etherington AM, Tansey P, Tait RC (2012) Polymorphisms in VKORC1 have more impact than CYP2C9 polymorphisms on early warfarin International Normalized Ratio control and bleeding rates. Br J Haematol 158:256-261
64. Luxembourg B, Schneider K, Sittinger K et al (2011) Impact of pharmacokinetic (CYP2C9) and pharmacodynamic (VKORC1, F7, GGCX, CALU, EPHX1) gene variants on the initiation and maintenance phases of phenprocoumon therapy. Thromb Haemost 105:169-180
65. McDonald MG, Rieder MJ, Nakano M, Hsia CK, Rettie AE (2009) CYP4F2 is a vitamin K1 oxidase: an explanation for altered warfarin dose in carriers of the V433M variant. Mol Pharmacol 75:1337-1346
66. McMillin GA, Melis R, Wilson A et al (2010) Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study. Ther Drug Monit 32:338-345
67. Millican EA, Lenzini PA, Milligan PE et al (2007) Genetic-based dosing in orthopedic patients beginning warfarin therapy. Blood 110:1511-1515
68. Mitchell C, Gregersen N, Krause A (2012) Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population. Pharmacogenomics 12:953-963
69. Moreau C, Bajolle F, Siguret V et al (2012) Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. Blood 119:861-867
70. Oldenburg J, Marinova M, Muller-Reible C, Watzka M (2008) The vitamin K cycle. Vitam Horm 78:35-62
71. Pautas E, Moreau C, Gouin-Thibault I et al (2010) Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. Clin Pharmacol Ther 87:57-64
72. Pavani A, Naushad SM, Mishra RC et al (2012) Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. Pharmacogenomics 13:869-878
73. Perera MA, Gamazon E, Cavallari LH et al (2011) The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans. Clin Pharmacol Ther 89:408-415
74. Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. BMJ 329:15-19
75. Rathore SS, Agarwal SK, Pande S, Singh SK, Mittal T, Mittal B (2012) Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. PLoS ONE 7:e37844
76. Rettie AE, Jones JP (2005) Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu Rev Pharmacol Toxicol 45:477-494
77. Rettie AE, Korzekwa KR, Kunze KL et al (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59
78. Rettie AE, Wienkers LC, Gonzalez FJ, Trager WF, Korzekwa KR (1994) Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics 4:39-42
79. Rieder MJ, Reiner AP, Gage BF et al (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352:2285-2293
80. Rieder MJ, Reiner AP, Rettie AE (2007) Gamma-glutamyl carboxylase (GGCX) tagSNPs have limited utility for predicting warfarin maintenance dose. J Thromb Haemost 5:2227-2234
81. Roberts JD, Wells GA, Le May MR et al (2012) Point-of-care genetic testing for personalisation of antiplatelet treatment (RAPID GENE): a prospective, randomised, proof-of-concept trial. Lancet 379:1705-1711
82. Rost S, Fregin A, Ivaskevicius V et al (2004a) Mutations in VKORC1 cause warfarin resistance and multiple coagulation factor deficiency type 2. Nature 427:537-541
83. Rost S, Fregin A, Koch D, Compes M, Muller CR, Oldenburg J (2004b) Compound heterozygous mutations in the gamma-glutamyl carboxylase gene cause combined deficiency of all vitamin K-dependent blood coagulation factors. Br J Haematol 126:546-549
84. Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE (2010) New genetic variant that might improve warfarin dose prediction in African Americans. Br J Clin Pharmacol 70:393-399
85. Sconce EA, Khan TI, Wynne HA et al (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106:2329-2333
86. Sconce EA, Daly AK, Khan TI, Wynne HA, Kamali F (2006) APOE genotype makes a small contribution to warfarin dose requirements. Pharmacogenet Genomics 16:609-611
87. Scott SA, Edelmann L, Kornreich R, Desnick RJ (2008) Warfarin pharmacogenetics: CYP2C9 and VKORC1 genotypes predict different sensitivity and resistance frequencies in the Ashkenazi and Sephardi Jewish populations. Am J Hum Genet 82:495-500
88. Shearer MJ, Newman P (2008) Metabolism and cell biology of vitamin K. Thromb Haemost 100:530-547
89. Shikata E, Ieiri I, Ishiguro S et al (2004) Association of pharmacokinetic (CYP2C9) and pharmacodynamic (factors II, VII, IX, and X; proteins S and C; and gamma-glutamyl carboxylase) gene variants with warfarin sensitivity. Blood 103:2630-2635
90. Si DY, Guo YJ, Zhang YF, Yang L, Zhou H, Zhong DF (2004) Identification of a novel variant CYP2C9 allele in Chinese. Pharmacogenetics 14:465-469
91. Sontag TJ, Parker RS (2007) Influence of major structural features of tocopherols and tocotrienols on their omega-oxidation by tocopherol-omega- hydroxylase. J Lipid Res 48:1090-1098
92. Stec DE, Roman RJ, Flasch A, Rieder MJ (2007) Functional polymorphism in human CYP4F2 decreases 20-HETE production. Physiol Genomics 30:74-81
93. Steward DJ, Haining RL, Henne KR et al (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3. Pharmacogenetics 7:361-367
94. Tai G, Farin F, Rieder MJ et al (2005) In-vitro and in vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose. Pharmacogenet Genomics 15:475-481
95. Takeuchi F, McGinnis R, Bourgeois S et al (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5:e1000433
96. Taube J, Halsall D, Baglin T (2000) Influence of cytochrome P-450CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment. Blood 96:1816-1819
97. Teichert M, Eijgelsheim M, Rivadeneira F et al (2009) A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 18:3758-3768
98. Tham LS, Goh BC, Nafziger A et al (2006) A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9. Clin Pharmacol Ther 80:346-355
99. Thijssen HH, Flinois JP, Beaune PH (2000) Cytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug metabolism and disposition: the biological fate of chemicals 28:1284-1290
100. Ufer M, Svensson JO, Krausz KW, Gelboin HV, Rane A, Tybring G (2004) Identification of cytochromes P450 2C9 and 3A4 as the major catalysts of phenprocoumon hydroxylation in vitro. Eur J Clin Pharmacol 60:173-182
101. van Schie RM, Wadelius MI, Kamali F et al (2009) Genotype-guided dosing of coumarin derivatives: the European pharmacogenetics of anticoagulant therapy (EU-PACT) trial design. Pharmacogenomics 10:1687-1695
102. van Schie RM, Wessels JA, le Cessie S et al (2011) Loading and maintenance dose algorithms for phenprocoumon and acenocoumarol using patient characteristics and pharmacogenetic data. Eur Heart J 32:1909-1917
103. Vecsler M, Loebstein R, Almog S et al (2006) Combined genetic profiles of components and regulators of the vitamin K-dependent gamma-carboxylation system affect individual sensitivity to warfarin. Thromb Haemost 95:205-211
104. Veenstra DL, You JH, Rieder MJ et al (2005) Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population. Pharmacogenet Genomics 15:687-691
105. Verhoef TI, Redekop WK, Buikema MM et al (2012) Long-term anticoagulant effects of the CYP2C9 and VKORC1 genotypes in acenocoumarol users. J Thromb Haemost 10:606-614
106. Visser LE, Trienekens PH, De Smet PA et al (2005) Patients with an ApoE epsilon4 allele require lower doses of coumarin anticoagulants. Pharmacogenet Genomics 15:69-74
107. Voora D, Koboldt DC, King CR et al (2010) A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clin Pharmacol Ther 87:445-451
108. Vorum H, Hager H, Christensen BM, Nielsen S, Honore B (1999) Human calumenin localizes to the secretory pathway and is secreted to the medium. Exp Cell Res 248:473-481
109. Wadelius M, Pirmohamed M (2007) Pharmacogenetics of warfarin: current status and future challenges. Pharmacogenomics J 7:99-111
110. Wadelius M, Sorlin K, Wallerman O et al (2004) Warfarin sensitivity related to CYP2C9, CYP3A5, ABCB1 (MDR1) and other factors. Pharmacogenomics J 4:40-48
111. Wadelius M, Chen LY, Downes K et al (2005) Common VKORC1 and GGCX polymorphisms associated with warfarin dose. Pharmacogenomics J 5:262-270
112. Wadelius M, Chen LY, Eriksson N et al (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121:23-34
113. Wadelius M, Chen LY, Lindh JD et al (2009) The largest prospective warfarin-treated cohort supports genetic forecasting. Blood 113:784-792
114. Wajih N, Sane DC, Hutson SM, Wallin R (2004) The inhibitory effect of calumenin on the vitamin K-dependent gamma-carboxylation system. Characterization of the system in normal and warfarin-resistant rats. J Biol Chem 279:25276-25283
115. Wallin R, Hutson SM, Cain D, Sweatt A, Sane DC (2001) A molecular mechanism for genetic warfarin resistance in the rat. Faseb J 15:2542-2544
116. Wang D, Chen H, Momary KM, Cavallari LH, Johnson JA, Sadee W (2008) Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement. Blood 112:1013-1021
117. Wei M, Ye F, Xie D et al (2012) A new algorithm to predict warfarin dose from polymorphisms of CYP4F2, CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. Thromb Haemost 107:1083-1091
118. Wu AH, Wang P, Smith A et al (2008) Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations. Pharmacogenomics 9:169-178
119. Yabe D, Taniwaki M, Nakamura T, Kanazawa N, Tashiro K, Honjo T (1998) Human calumenin gene (CALU): cDNA isolation and chromosomal mapping to 7q32. Genomics 49:331-333
120. You JHS, Tsui KKN, Wong RSM, Cheng G (2012) Cost-effectiveness of dabigatran versus genotype-guided management of warfarin therapy for stroke prevention in patients with atrial fibrillation. PloS One 7:e39640
121. Yuan HY, Chen JJ, Lee MTM et al (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14:1745-1751
122. Zhang X, Li L, Ding X, Kaminsky LS (2011) Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose. Drug Metab Dispos 39:1433-1439
123. Zhu Y, Shennan M, Reynolds KK et al (2007) Estimation of warfarin maintenance dose based on VKORC1 (-1639 G > A) and CYP2C9 genotypes. Clin Chem 53:1199-1205